A new study in the journal JAMA Network Open has found the rate of Guillain–Barré syndrome (GBS) amongst those “vaccinated” with the J&J injection is “significantly higher than the background rate.”
In a new study published in the medical journal JAMA Network Open epidemiologist Kayla Hanson, et al. say that—after a review of surveillance data from the CDC’s Vaccine Safety Datalink–the rate of Guillain–Barré syndrome (GBS) for those “vaccinated” with the Johnson & Johnson COVID-19 injection have an incidence rate of confirmed GBS that is “significantly higher than the background rate of GBS.” The syndrome, which causes symptoms such as rapid-onset muscle weakness and dangerous abnormalities in heart rate and blood pressure, has a global fatality rate of 7.5%.
Hanson and her colleagues observed this increase in GBS in J&J injection recipients after reviewing surveillance data from the Vaccine Safety Datalink (VSD). As the CDC notes, its VSD is a collaborative project between the CDC’s “Immunization Safety Office” and nine participating health care organizations that aims ” to monitor safety of vaccines and conduct studies about rare and serious adverse events following immunization.”
The researchers used VSD surveillance data from eight participating health care systems in the U.S., including 10,158,003 participants, age 12 and up. From December 13, 2020 through November 13, 2021, 15,120,073 doses of COVID-19 “vaccines” were administered to 7,894,989 individuals (out of the 10.15 million participants in the VSD database); including 483,053 J&J doses, 8,806,595 Pfizer doses, and 5,830,425 Moderna doses. The researchers identified 11 “confirmed” cases of GBS after the 483,053 J&J injections. Hanson et al. note that “The unadjusted incidence rate of GBS per 100,000 person-years in the 1 to 21 days after [the J&J injection] was 32.4… significantly higher than the background rate.”
“Significantly higher than the background rate” indeed. The researchers report the “incidence of GBS in the 21 days after [the J&J injection] was 32.4 per 100,000 person-years, which was substantially greater than the expected background rate of 1 to 2 per 100,000 person-years.” I.e. there was a 15- to 30-fold increase in the incidence of GBS in J&J injection recipients versus the normal background rate. (For reference, “person years” is a type of measurement that takes into account both the number of people in a study and the amount of time each person spends in the study.)
The researchers say that during the period spanning between 1 and 84 days after injection with the J&J “vaccine,” 22 “potential” cases of GBS were identified; after adjudication, 11 (50%) were confirmed. Symptoms for those afflicted are not described in depth in the study—there is mention of “facial weakness or paralysis, in addition to weakness and decreased reflexes in the limbs” in those affected—although the range of ailments GBS causes is wide and replete with nightmare scenarios. (Ten patients were hospitalized, or 91%, and all were treated with intravenously.)
GBS, also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP), is, as Johns Hopkins Medicine notes, “a neurological disorder in which the body’s immune system attacks the peripheral nervous system, the part of the nervous system outside the brain and spinal cord.”
Regarding symptoms, Johns Hopkins notes:
“The first symptom includes weakness or tingling sensations in the legs. This sometimes spreads to the arms and upper body. A neurological exam usually reveals a loss of all deep tendon reflexes. The symptoms may get worse. In some cases, you may not be able to use your muscles at all. You become paralyzed, and breathing is hard. Your blood pressure and heart function are affected. GBS is a medical emergency and needs to be treated promptly.
“Although symptoms can become life-threatening, partial recovery is possible from even the most severe cases of GBS. But you may always have some degree of weakness.”
Not only did the researchers observe an adverse-event signal for GBS, they also note that “In July 2021, data from the Vaccine Adverse Event Reporting System (or VAERS, a glimpse of which is immediately above) indicated that the reporting rate of Guillain-Barré syndrome (GBS), a rare neurological disorder, was higher after [the J&J injection] than after mRNA vaccines.”
In fact, the researchers went further and said “Our analyses also included GBS cases confirmed by medical record review and adjudication, and thus provide validation of the preliminary VAERS findings based on presumptive GBS.”
Not only does this study evince a serious GBS signal, as well as validate preliminary VAERS findings, there have also been numerous other reports of a correlation between the COVID-19 injections and GBS. Another study published in JAMA on October 7, 2021—referenced by Hanson et al.—found that “reports of presumptive GBS” were identified in VAERS indicating “a potential small but statistically significant safety concern for Guillain-Barré syndrome following receipt of the [J&J] vaccine.”
Likewise, there are many case reports of GBS after COVID-19 “vaccination” already in the literature. And they’re not exclusive to the Johnson & Johnson injection either.
In a letter to the editor of Neurological Sciences, Michele Trimboli, et al. described a 25-year-old woman who experienced a case of GBS following her second dose of Pfizer’s COVID-19 “vaccine.” The woman, who was without comorbidities, reported “difficulty in walking and climbing stairs associated to paresthesias and numbness in the anterolateral region of the right thigh.” The woman also had “steppage gait due to bilateral feet drop,” and “an important muscle weakness in her foot flexors.”
In another case report published on June 29, 2021 in BMJ Case Reports, Tanveer Hasan, et al. described a case of a 62-year-old woman who presented with “paraesthesia and progressive weakness of both lower limbs over 3 days.” Initially, the distal muscles were involved, which then progressed to involve the proximal muscles of both lower limbs and finally ascending to affect both the arms. Along with that, the woman also reportedly suffered from “neuropathic pain in the posterior aspects of both legs.” These effects occurred after she received her first dose of the AstraZeneca COVID-19 “vaccine.”
The danger of GBS after COVID-19 “vaccination” isn’t new either. In a study published in Cureus on February 18, 2021, Sadia Waheed, et al. reported an 82-year-old “highly functional female” experiencing a case of GBS after receiving the Pfizer injection. The woman also reported “increased difficulty in walking to the point where she had to use a walker for ambulation.” She “subsequently sustained a fall due to her weakness, which prompted her [to visit] the emergency room.”
In a case series review published in Emerging Infectious Diseases on December 27, 2021, Shih-Chieh Shao reported 38 cases of GBS related to COVID-19 vaccination from 17 publications across nine countries. The authors reported that “most…case-patients had a diagnosis of acute inflammatory demyelinating polyneuropathy (23/33), followed by acute motor and sensory axonal neuropathy (4/33) and acute motor axonal neuropathy.” Nine case-patients required “mechanical ventilation during hospitalization.” One died.
In July of 2021, the FDA itself added a warning to the Johnson & Johnson “vaccine” after approximately 100 people developed GBS. (The CBS tweet above reports on the implementation of the warning.)
NOTE: Regarding the mRNA “vaccines” (from Pfizer and Moderna), Hanson, et al. found there was “no difference” in risk for developing GBS relative to background rates.
Feature image: Internet Archive Book Images
Related News
